Endocyte, Inc. (NASDAQ:ECYT) VP Christopher P. Leamon sold 23,231 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $5.04, for a total transaction of $117,084.24. Following the sale, the vice president now owns 150,579 shares of the company’s stock, valued at approximately $758,918.16. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Endocyte, Inc. (ECYT) traded down $0.31 during mid-day trading on Monday, reaching $4.81. 1,935,099 shares of the company’s stock were exchanged, compared to its average volume of 1,179,099. Endocyte, Inc. has a fifty-two week low of $1.17 and a fifty-two week high of $6.55.

Endocyte (NASDAQ:ECYT) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.20). The business had revenue of $0.03 million for the quarter. Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.21) EPS. equities research analysts forecast that Endocyte, Inc. will post -1.24 earnings per share for the current fiscal year.

A number of brokerages have commented on ECYT. ValuEngine lowered shares of Endocyte from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Zacks Investment Research upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Thursday, November 9th. Wedbush upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $2.00 to $7.00 in a research note on Tuesday, October 3rd. Finally, Cowen restated a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd.

Hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its stake in Endocyte by 1,064.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock valued at $646,000 after purchasing an additional 393,975 shares in the last quarter. FMR LLC boosted its holdings in Endocyte by 0.9% during the 2nd quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock worth $5,310,000 after acquiring an additional 31,168 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Endocyte by 4.7% during the 1st quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after acquiring an additional 6,469 shares during the last quarter. Spark Investment Management LLC purchased a new position in Endocyte during the 2nd quarter worth $177,000. Finally, LMR Partners LLP purchased a new position in Endocyte during the 2nd quarter worth $196,000. Institutional investors and hedge funds own 17.68% of the company’s stock.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/04/endocyte-inc-ecyt-vp-sells-117084-24-in-stock.html.

Endocyte Company Profile

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.